Drug Profile

BMN 331

Alternative Names: BMN-331

Latest Information Update: 02 May 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator BioMarin Pharmaceutical
Class Gene therapies; Vascular disorder therapies
Mechanism of Action Complement C1 inhibitor protein replacements; Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Hereditary angioedema
New Molecular Entity No

Highest Development Phases

Discontinued Hereditary angioedema

Most Recent Events

24 Apr 2024 Discontinued - Phase-I/II for Hereditary angioedema in Spain (IV), due to portfolio prioritization
24 Apr 2024 Discontinued - Phase-I/II for Hereditary angioedema in USA (IV), due to portfolio prioritization
06 Oct 2022 Phase-I/II clinical trials in Hereditary angioedema in Spain (IV) (EudraCT-2021-003603-18)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com